Valneva SE (VLA.PA) trades at €4.53 after hours on 13 Mar 2026, down -5.31% on the day, as investors position ahead of Q4 results and a scheduled earnings call. The biotech’s upcoming report and management commentary on vaccine sales and R&D spend are the immediate catalysts for VLA.PA stock. Volume is elevated at 839,847 shares versus a 30‑day average of 1,025,640, signalling higher trader interest. We summarise the key figures, model-driven forecasts, and what to watch in the EURONEXT Europe session for VLA.PA stock.
VLA.PA stock: price action and market context
Valneva (VLA.PA) closed the regular session at €4.78 and is trading after hours at €4.53, a -5.31% intraday move. The 52‑week range is €2.25 to €5.42, with a market capitalisation of €775,775,760.00 and 172,088,678 shares outstanding. Sector peers in Healthcare show muted short‑term performance, and biotech volatility is higher than the sector average, increasing sensitivity around the earnings release.
Earnings preview: what to expect from the VLA.PA earnings report
Valneva reports Q4 results and commentary on commercial uptake of IXIARO and progress on VLA1553 and VLA15, with the earnings announcement set for the week of 18 Mar 2026. Analysts will focus on revenue growth, margin trajectory, and R&D cadence; management guidance or updates to the pipeline timetable could swing shares. Recent headline risk includes share price drops tied to market updates on product demand, making guidance the primary near‑term driver for VLA.PA earnings.
Financials and key ratios investors should note
Recent trailing metrics show EPS -0.65 and a negative PE of -6.94, while the 50‑day average price is €4.33 and the 200‑day average is €3.82. Valneva’s price‑to‑sales ratio is 4.34 and price‑to‑book is 4.90, reflecting premium valuation on modest revenue per share. The company has a current ratio of 1.78 and debt‑to‑equity of 1.30, underlining leverage that investors must track alongside free cash flow trends.
Meyka AI rates VLA.PA and technical view
Meyka AI rates VLA.PA with a score of 61.69 out of 100 (Grade B, suggestion: HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, forecasts, and analyst consensus. Technicals show RSI 49.19, MACD histogram near -0.03, and Bollinger middle band at €4.67, implying a neutral short‑term momentum for VLA.PA stock.
Price forecasts and analyst lens on VLA.PA forecast
Meyka AI’s forecast model projects a yearly target of €5.04, implying an upside of 11.29% from the current €4.53 price. Shorter horizons vary: a quarterly model target is €5.73 (+26.49%) and a monthly model sits at €3.86 (‑14.79%). These model‑based projections are not guarantees and depend on reported revenue, R&D updates, and market reception to guidance.
Risks and opportunities for VLA.PA investors
Key opportunities include progress in the chikungunya Phase III VLA1553 programme and stronger traveler vaccine sales for IXIARO and DUKORAL. Risks include continued negative EPS, funding needs if commercial momentum slows, and sensitivity to regulatory or partner developments. With elevated inventory days and tight cash conversion cycles, operational execution will influence VLA.PA stock performance after the earnings report.
Final Thoughts
Key takeaways for VLA.PA stock heading into after‑hours trading on 13 Mar 2026: Valneva sits at €4.53 with elevated volume and a clear earnings catalyst in the coming week. Financials show negative EPS (-0.65) and leverage with debt‑to‑equity 1.30, but revenue per share growth and improving margins are areas to watch. Meyka AI’s forecast model projects a €5.04 yearly target, an implied upside of 11.29% versus the current price, while the quarterly target of €5.73 implies a larger 26.49% potential move if guidance is upbeat. Conversely, the monthly model at €3.86 shows downside risk if sales or R&D guidance disappoints. Investors should focus on revenue beats, margin commentary, and any update on VLA1553 timing. This analysis uses model‑based projections from Meyka AI and should not be taken as investment advice. For live updates and the full data sheet on Valneva, see our coverage at Valneva on Meyka.
FAQs
When does Valneva report earnings and how could it move VLA.PA stock?
Valneva’s earnings event is scheduled for the week of 18 Mar 2026. Expect price sensitivity to revenue versus guidance and pipeline updates; strong commercial or clinical news could lift VLA.PA stock, while weak guidance may pressure the share price.
What are the most important metrics to watch in the VLA.PA earnings report?
Watch revenue growth, gross margin, R&D spend, free cash flow, and management guidance on VLA1553 and VLA15. Given EPS -0.65, cash flow and funding commentary are particularly relevant for VLA.PA stock.
What is Meyka AI’s short‑term forecast for VLA.PA stock?
Meyka AI’s model gives a monthly projection of €3.86 and a quarterly projection of €5.73. These model projections signal possible short‑term downside or upside depending on the earnings tone, and are not guaranteed outcomes.
How does valuation look for Valneva on EURONEXT?
Valneva trades at price‑to‑sales 4.34 and price‑to‑book 4.90, with negative PE -6.94. These ratios reflect premium expectations versus current profitability and underline the importance of upcoming commercial results for VLA.PA stock.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)